Edgewise Therapeutics Inc Market Cap ($3.66 Billion)
Market Cap & Net Worth: Edgewise Therapeutics Inc (EWTX)
Edgewise Therapeutics Inc market cap. Edgewise Therapeutics Inc (NASDAQ:EWTX) has a market capitalization of $3.66 Billion ($3.66 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4203 globally and #1487 in its home market, demonstrating a -2.73% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Edgewise Therapeutics Inc's stock price $38.90 by its total outstanding shares 107593006 (107.59 Million). Also see Edgewise Therapeutics Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Edgewise Therapeutics Inc Market Cap History (2021–2026)
Edgewise Therapeutics Inc market cap history from 2021 to 2026. Data shows growth from $1.64 Billion to $4.19 Billion (4.75% CAGR). Check Edgewise Therapeutics Inc (EWTX) stock price for real-time trading data and today's change.
Index Memberships
Edgewise Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.14% | #111 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #492 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.20% | #70 of 263 |
Weight: Edgewise Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Edgewise Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Edgewise Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Edgewise Therapeutics Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of EWTX by Market Capitalization
Companies near Edgewise Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see Edgewise Therapeutics Inc (EWTX) total assets for a full breakdown of the balance sheet.
Key companies related to Edgewise Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Edgewise Therapeutics Inc (2021–2026)
Market capitalization of Edgewise Therapeutics Inc from 2021 to today. Between 2021 and today, Edgewise Therapeutics Inc's market cap moved from $1.64 Billion to $ 4.19 Billion, with a yearly change of 4.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $4.19 Billion | +56.76% |
| 2025 | $2.67 Billion | -7.06% |
| 2024 | $2.87 Billion | +144.06% |
| 2023 | $1.18 Billion | +22.37% |
| 2022 | $961.88 Million | -41.49% |
| 2021 | $1.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Edgewise Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.66 Billion USD |
| MoneyControl | $3.66 Billion USD |
| MarketWatch | $3.66 Billion USD |
| marketcap.company | $3.66 Billion USD |
| Reuters | $3.66 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Edgewise Therapeutics Inc
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company… Read more